Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada

Vaccine

Volumn 33, Issue 23, 2015, Pages 2684-2689

  Deceuninck, Geneviève ^a   De Serres, Gaston ^a,b,c   Boulianne, Nicole ^a,b   Lefebvre, Brigitte ^b   De Wals, Philippe ^a,b,c  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Case control study; Effectiveness; Invasive pneumococcal disease; Pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

ARTICLE; CANADA; CHILD; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; HEALTH INSURANCE; HUMAN; IMMUNIZATION; INFANT; INVASIVE INFECTIOUS DISEASE; PHARMACOLOGICAL PARAMETERS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; TELEPHONE INTERVIEW; VACCINE EFFECTIVENESS; BACTEREMIA; CASE CONTROL STUDY; FEMALE; IMMUNOLOGY; MALE; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; TREATMENT OUTCOME;

BACTEREMIA; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUEBEC; TREATMENT OUTCOME; VACCINES, CONJUGATE;

EID: 84929047591     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.005     Document Type: Article

References (23)

1. Butler J.C. Epidemiology of pneumococcal disease. The pneumococcus 2004, 136-147. ASM Press, Washington, DC. E.I. Tuomanen, T.J. Mitchell, D.A. Morrison, B.G. Spratt (Eds.).
2. National Advisory Committee on Immunization (NACI) Statement on recommended use of pneumococcal conjugate vaccine. CCDR 2002, vol. 28 (ACS-2):1-32.
3. Quebec Immunization Committee Assessment of the appropriateness of an immunization program for pneumococcal infections in children using a reduced number of doses of conjugate vaccine 2005, Institut national de santé publique du Québec, Quebec City, Available at: http://www.inspq.qc.ca/pdf/publications/391-ImmunizationConjugateVaccine.pdf.
4. De Wals P., Boulianne N., Sévin É., Ouakki M., Deceuninck G., Guay M. Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs. Can J Publ Health 2009, 100:413-416.
5. Boulianne N., Bradet R., Audet D., Ouakki M. Enquête sur la couverture vaccinale des enfants de 1 an et 2 ans au Québec en 2012 2013, Institut national de santé publique du Québec, Quebec City, Available at: http://www.inspq.qc.ca/pdf/publications/1651_EnquCouvVaccinEnfants1Et2Ans2012.pdf.
6. Comité sur l'immunisation du Québec (CIQ) Évaluation de la pertinence d'un nouveau vaccin antipneumococcique conjugué au Québec 2009, Institut national de santé publique du Québec, Quebec City, Available at: http://www.inspq.qc.ca/pdf/publications/933_EvalVaccAntipneumo.pdf.
7. Comité sur l'immunisation du Québec (CIQ) Évaluation de deux nouveaux vaccins pneumococciques conjugués pour l'immunisation des enfants au Québec 2010, Institut national de santé publique du Québec, Quebec City, Available at: http://www.inspq.qc.ca/pdf/publications/1172_Eval2VaccinsPneumocoConjuguesImmuEnfants.pdf.
8. Public Health Agency of Canada National Surveillance of Invasive Streptococcus pneumoniae and Streptococcus pyogenes in Canada. Annual Summary 2012, Available at: http://publications.gc.ca/collections/collection_2014/aspc-phac/HP57-2-2012-eng.pdf.
9. Lefebvre B. Programme de surveillance du pneumocoque. Rapport 2012 2013, Institut national de santé publique du Québec, Quebec City, Available at: http://www.inspq.qc.ca/pdf/publications/1734_ProgSurvPneumoQc_RappAnnu2012.pdf.
10. Deceuninck G., De Wals P., Bouliannne N., De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2010, 29:546-549.
11. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187-195.
12. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
13. Poolman J., Frasch C., Nurkka A., Käyhty H., Biemans R., Schuerman L. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol 2011, 18:327-336.
14. Hausdorff W.P., Hoet B., Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?. BMC Pediatr 2010, 10(4). 10.1186/1471-2431-10-4.
15. Palmu A.A., Jokinen J., Borys D., et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenza protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013, 381:214-222.
16. Domingues C.M., Verani J.R., Montenegro Renoiner E.I.M., de Cunto Brandileone M.C., Flannery B., de Oliveira L.H., et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014, 2:464-471. 10.1016/S2213-2600(14)70060-8.
17. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination. An alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303:549-552.
18. Miller E., Andrews N.J., Waight P.A., Slack M.P.E., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
19. Singleton R., Wenger J., Klejka J.A., Bulkow L.R., Thompson A., Sarkozy D., et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska Native children: results of a clinical trial. Pediatr Infect Dis J 2013, 32:257-263.
20. Grimprel E., Laudat F., Patterson S., Baker S.A., Sidhu M.S., Gruber W.C., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine 2011, 29:9675-9683.
21. Orenstein W.A., Bernier R.H., Dondero T.J., Hinman A.R., Marks J.S., Bart K.J., et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985, 63:1055-1068.
22. Steens A., Riise Bergsaker M.A., AAberge I.S., Rønning K., Vestrheim D.F. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013, 31:6232-6238.
23. De Wals P., Lefebvre B., Markowski F., Deceuninck G., Defay F., Douville-Fradet M., et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2014, 32:1501-1506.